A novel de novo activating mutation in STAT3 identified in a patient with common variable immunodeficiency (CVID)
Russell, MA; PIgors, M; Houssen, M; et al.Manson, A; Kelsell, D; Longhurst, H; Morgan, NG
Date: 24 November 2017
Journal
Clinical Immunology
Publisher
Elsevier for Clinical Immunology Society
Publisher DOI
Abstract
Common variable immunodeficiency (CVID) is characterised by repeated infection
associated with primary acquired hypogammaglobulinemia. CVID frequently has a complex
aetiology but, in certain cases, it has a monogenic cause. Recently, variants within the gene
encoding the transcription factor STAT3 were implicated in monogenic CVID. ...
Common variable immunodeficiency (CVID) is characterised by repeated infection
associated with primary acquired hypogammaglobulinemia. CVID frequently has a complex
aetiology but, in certain cases, it has a monogenic cause. Recently, variants within the gene
encoding the transcription factor STAT3 were implicated in monogenic CVID. Here, we
describe a patient presenting with symptoms synonymous with CVID, who displayed
reduced levels of IgG and IgA, repeated viral infections and multiple additional comorbidities.
Whole-exome sequencing revealed a de novo novel missense mutation in the
coiled-coil domain of STAT3 (c.870A>T; p.K290N). Accordingly, the K290N variant of STAT3
was generated, and a STAT3 responsive dual-luciferase reporter assay revealed that the
variant strongly enhances STAT3 transcriptional activity both under basal and stimulated
(with IL-6) conditions. Overall, these data complement earlier studies in which CVIDassociated
STAT3 mutations are predicted to enhance transcriptional activity, suggesting
that such patients may respond favourably to IL-6 receptor antagonists (e.g. tocilizumab).
Institute of Biomedical & Clinical Science
Collections of Former Colleges
Item views 0
Full item downloads 0